The role of treatment adherence after myocardial infarction (according to the acute myocardial infarction registry)

Aim. To evaluate the effects of long-term treatment adherence in the post-infarction period, taking into account the clinical and demographic data of patients and the prescribed drug therapies.

Methods. A total of 115 patients who survived after myocardial infarction and recruited in the Acute Myocardial Infarction Registry were enrolled in the study. Patients were followed up for 5 years. Treatment adherence was evaluated with the Moriscos-Green scale. Obtained data were processed using the commercially available software Statistica 10.0 and SPSS Statistics Desktop 22.0.

Results. Only 45% of patients who survived after myocardial infarction, strictly followed the recommendations of the attending physician regarding the prescribed drug therapy. The Kaplan-Mayer estimator reported that adherence to treatment in patients with myocardial infarction had a more significant role than the compliance of drug therapy with the existing guidelines. However, the mean values of the lipid profile did not reach the target levels regardless of patients’ adherence. In addition, one patient out of five who was strictly adhered to the medical recommendations did not reach the target levels of blood pressure.

Conclusion. Adherence to treatment is an independent determinant of the effectiveness of secondary prevention of coronary artery disease. Failure to adhere medical recommendations by patients after myocardial infarction leads to a multiple increase in the likelihood of adverse cardiovascular events. However, failure to achieve the target lipid and blood pressure goals even in those patients who were strictly adhered to treatment may be associated with insufficient doses of drugs, thereby requiring particular attention and concern.

1. Cardiovascular prevention 2017. National guidelines. 2. Federal state statistics service: health care. Available at: http:// Russian Journal of Cardiology. 2018; (6): 7-122. (In Russian)doi:10.15829/1560-4071-2018-6-7-122.

2. Federal state statistics service: health care. Available at: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/healthcare/ (accessed 07.06.2019) (In Russian)

3. Aronov D.M., Bubnova M.G., Barbarash O.L., et al. Acute myocardial infarction with ST-elevation of the electrocardiogram: rehabilitation and secondary prevention: Russian clinical guidelines. Cardiosomatics 2014: app. 1: 5-42. (In Russian)

4. Haynes R.B., Taylor D.W., Sackett D.L., et al. Determinants of compliance: The disease and the mechanics of treatment. Compliance in health care. Johns Hopkins University Press 1979: 49-62.

5. Lukina Y.V, Kutishenko N.P., Martsevich S.Y The problem of adherence to the treatment in modern medicine: possibilities of solution, impact on the effectiveness of therapy and disease outcomes. Rational Pharmacotherapy in Cardiology. 2017; 13 (4): 519-524. (In Russian) doi:10.20996/1819-6446-2017-13-4-519-524

6. Sedykh D.YU., Petrov G.P., Kashtalap V.V. Differences in adherence behaviour patterns in patients with primary and recurrent myocardial infarction. 2018; 7 (4): 15-25. (In Russian) doi: 10.17802/2306-1278-2018-7-4-15-25

7. Zullig L.L., Ramos K., Bosworth H.B. Improving Medication Adherence in Coronary Heart Disease. Current Cardiology Reports. 2017; 19 (11): 113. doi: 10.1007/s11886-017-0918-y.

8. Haase J., Farris K.B., Dorsch M.P. Mobile Applications to Improve Medication Adherence. Telemed J E Health. 2017; 23 (2): 75-79. doi: 10.1089/tmj.2015.0227

9. Nafradi L., Nakamoto K., Schulz PJ. Is patient empowerment the key to promote adherence? A systematic review of the relationship between self-efficacy, health locus of control and medication adherence. PLoS One. 2017; 12 (10): e0186458. doi: 10.1371/joumal.pone.0186458

10. Garganeeva A.A, Okrugin S.A., Borel K.N., Kuzheleva E.A., Parshin E.A. Myocardial infarction at the border of two centuries: demographic and social tendencies. Clinical medicine 2016; 6: 463-466. (In Russian)

11. Safronenko V.A, Chesnikova A.I., Khripun A.V Features of coronary heart disease in patients with 5-year history of myocardial infarction depending of adherence. Medical Herald of the South of Russia. 2013; 1: 60-63. (In Russian)

12. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. EurHeart J. 2016; 37 (39): 2999-3058. doi: 10.1093/eurheartj/ehw272.

13. Garganeeva A.A, Kuzheleva E.A, Efimova E.V., Tukish O.V. Drug therapy of patients with myocardial infarction as the most important component of a polyclinic stage of cardiorehabilitation. Cardiosomatics. 2015; 3: 22-26. (In Russian)